A Prospective Randomized Controlled Trial of Morphine versus Oxycodone for Cancer Pain: Genetic Determinants of Response to Opioids

The Royal Marsden NHS Foundation Trust (UK)0 个研究点目标入组 200 人开始时间: 2005年3月29日最近更新: 2016年10月17日

适应症

试验速览

暂无简介。

•1. Patients must have a clinical or histological diagnosis of cancer
•2. Patients whose pain is not controlled on Step 2 (weak opioid) analgesics (as defined by the WHO analgesic ladder) who clinically require a strong opioid
•3. Patients must be over 18 years of age
•4. Patients must be able to give written informed consent
•5. Patients must be willing to undergo genetic screening

•Current exclusion criteria as of 23/06/2011:
•1. Patients with renal failure (1.5x ULN). These patients should be treated with alfentanil as per Palliative Care Clinical Guidelines
•2. Patients must not currently be taking regular strong opioids
•3. Patients requiring parenteral administration of opioids
•4. Patients with predominantly incident pain
•5. Patients with a clearly defined history of intolerance to morphine or oxycodone
•6. Patients who are pregnant
•Previous exclusion criteria:
•1. Patients with renal failure (1.5 x upper limit of normal [ULN]). These patients should be treated with alfentanil as per palliative care guidelines.
•2. Patients must not have been taking regular Step 3 analgesics in the last month
•3. Patients requiring parenteral administration of opioids
•4. Patients with predominantly neuropathic pain
•5. Patients with predominantly incident pain
•6. Patients with a clearly defined history of intolerance to morphine or oxycodone

发起方

The Royal Marsden NHS Foundation Trust (UK)